Straits Times Index
3,146.48 -37.13 (-1.17%) Nikkei
38,471.20 -761.60 (-1.94%) Hang Seng
16,233.85 -366.61 (-2.21%) FTSE 100
7,853.04 -112.49 (-1.41%) Bitcoin USD
63,522.89 -2,853.14 (-4.30%) CMC Crypto 200
885.54 0.00 (0.00%)
DMK Pharmaceuticals Corporation (0A4X.L)
| Previous close | 0.0521 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 10,485 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2730 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireDMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generationSAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (Nasdaq: DMK) (“DMK”), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, announces that it has regained the full rights to commercialize ZIMHI® (naloxone) after the termination of an exclus
- GlobeNewswire
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
Now seeking out license opportunities for SYMJEPI®SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced that it is reacquiring the rights to its SYMJEPI® (epinephrine) Injection 0.3mg and SYMJEPI® (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”)
- GlobeNewswire
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI® and thus increase shareholder value Developed holistic company growth strategy to create a cost effective, coordinated, streamlined approach to operations to increase value for patients and shareholders Presented preclinical data for DPI-125 at the Society of Neuroscience Annual Meeting 2023 on Novem
